respiratori
syncyti
viru
rsv
major
caus
respiratori
diseas
cattl
young
children
despit
develop
vaccin
bovin
b
rsv
incomplet
protect
exacerb
subsequ
rsv
diseas
occur
order
circumv
problem
calv
vaccin
nucleocapsid
protein
known
major
target
cell
cattl
perform
accord
dna
primeprotein
boost
strategi
result
show
dna
vaccin
prime
specif
tcellmedi
respons
indic
lymphoprolif
respons
product
respons
enhanc
protein
boost
challeng
mockvaccin
calv
display
gross
pneumon
lesion
viral
replic
lung
contrast
calv
vaccin
success
administr
plasmid
dna
protein
exhibit
protect
develop
pneumon
lesion
viral
replic
bal
fluid
lung
protect
correl
cellmedi
immun
antibodi
respons
rsv
major
caus
hospit
infant
less
year
age
like
human
counterpart
bovin
respiratori
syncyti
viru
brsv
major
caus
calf
morbid
mortal
calv
less
year
age
particularli
suscept
diseas
matern
antibodi
respiratori
syncyti
viru
prevent
infect
calv
antibodi
seem
decreas
sever
infect
furthermor
brsv
one
virus
contribut
bovin
respiratori
diseas
complex
protect
brsv
afford
vaccin
describ
numer
vaccin
licens
wide
use
field
howev
exacerb
respiratori
diseas
induc
calv
infant
vaccin
formalininactiv
brsv
vaccin
mice
enhanc
diseas
immunopatholog
basi
character
polar
type
respons
increas
product
associ
pulmonari
histopatholog
eosinophilia
calv
enhanc
patholog
associ
elev
ige
titer
mark
eosinophilia
suggest
immun
respons
addit
author
report
high
mortal
calv
subsequ
use
inactiv
vaccin
field
thu
need
protect
vaccin
abl
confer
protect
neonat
even
presenc
matern
antibodi
lack
diseas
exacerb
side
effect
previous
shown
f
g
surfac
glycoprotein
n
protein
major
protect
antigen
brsv
neutral
antibodi
f
protein
mediat
protect
howev
serum
antibodi
provid
greater
contribut
reduc
brsv
induc
lower
respiratori
diseas
upper
respiratori
tract
viru
shed
cellmedi
immun
also
critic
paramet
outcom
rsv
infect
f
p
g
n
protein
antigen
target
recogn
bovin
cell
latter
two
protein
also
specif
target
murin
protein
murin
human
n
protein
cell
cell
constitut
major
lymphocyt
subpopul
respiratori
tract
calv
recov
brsv
infect
deplet
cell
also
induc
delay
viru
clearanc
lung
nasopharyng
calv
mice
diminish
ctl
activ
migrat
lung
treatment
delay
viral
clearanc
furthermor
prime
rsvspecif
respons
suppress
eosinophilia
induc
challeng
anim
vaccin
g
glycoprotein
dna
vaccin
effect
way
gener
humor
cellmedi
respons
intramuscular
vaccin
mice
plasmid
dna
express
f
g
protein
rsv
shown
induc
strong
respons
reduc
viral
load
lung
rsv
challeng
without
induc
enhanc
pulmonari
inflammatori
respons
eosinophilia
howev
gener
recogn
dna
vaccin
often
less
effect
larg
anim
mice
improv
immun
respons
achiev
boost
anim
previous
vaccin
plasmid
dna
inactiv
vaccin
approach
success
use
protect
calv
bovin
challeng
strategi
also
success
use
previou
brsv
experi
calv
vaccin
codonoptim
plasmid
dna
express
f
n
brsv
protein
boost
inactiv
commerci
vaccin
protect
clinic
sign
gross
pneumon
lesion
viru
replic
studi
humor
cellmedi
immun
respons
prime
dna
inject
enhanc
protein
boost
reduc
clinic
sign
viru
replic
brsv
challeng
use
f
protein
rsv
primeboost
protocol
also
repres
interest
strategi
earli
life
immun
purpos
work
present
investig
protect
calv
brsv
focus
mainli
stimul
brsv
cellmedi
immun
therefor
combin
plasmid
protein
vaccin
perform
n
protein
immunogen
protect
confer
vaccin
scheme
evalu
brsv
challeng
plasmid
express
synthet
dna
sequenc
code
orf
n
protein
brsv
pnsyn
describ
elsewher
larg
scale
plasmid
dna
purifi
transform
top
bacteria
cell
affin
chromatographi
anionexchang
resin
plasmid
giga
kit
qiagen
purifi
n
protein
obtain
recombin
baculoviru
express
code
sequenc
n
protein
brsv
strain
briefli
n
gene
clone
vector
invitrogen
recombin
baculoviru
express
n
protein
bacn
obtain
transfect
insect
cell
recombin
plasmid
purif
plaqu
recommend
manufactur
cell
infect
bacn
moi
cell
harvest
h
pi
least
cell
lyse
wash
pb
resuspend
trishcl
mm
ph
nacl
imidazol
mm
buffer
n
protein
purifi
ninta
resin
qiagen
batch
recommend
manufactur
protein
concentr
determin
bca
protein
assay
pierc
accord
manufactur
recommend
expect
protein
kda
purifi
analyz
page
fig
prior
immun
quila
adjuv
ad
n
protein
final
concentr
mgml
brsv
viru
grown
calf
primari
kidney
cell
minim
eagl
medium
mem
gibco
brl
supplement
fetal
calf
serum
mgml
gentamycin
iu
penicillin
challeng
inoculum
consist
lung
lavag
fluid
calf
collect
intratrach
inocul
brsv
strain
describ
previous
inoculum
contain
tcid
ml
free
bovin
viral
diarrhea
viru
bovin
bovin
parainfluenza
bovin
coronaviru
bovin
endotoxin
bacteria
mycoplasma
back
titrat
confirm
amount
viru
inocul
fourteen
crossbr
dairi
calv
week
age
randomli
alloc
experiment
group
anim
hous
ident
condit
stabl
calv
shown
seroneg
brsv
bovin
viral
diarrhea
viru
start
experi
shown
tabl
calv
vaccin
twice
week
interv
day
g
pnsyn
plasmid
dna
salin
first
vaccin
dose
inject
intramuscularli
second
dose
administr
intraderm
site
neck
seven
calv
subject
protocol
control
plasmid
four
week
second
dna
administr
day
respect
calv
inject
pnsyn
control
plasmid
subject
intramuscular
inject
g
purifi
n
protein
adjuv
quil
ml
volum
calv
treat
salin
three
week
third
vaccin
day
calv
challeng
brsv
strain
intratrach
ml
inject
combin
intranas
nebul
ml
calv
examin
daili
challeng
follow
clinic
sign
cough
nasal
discharg
anorexia
depress
rectal
temperatur
respiratori
rate
sera
heparin
treat
blood
collect
prior
vaccin
day
challeng
day
day
challeng
day
examin
humor
cellmedi
respons
bronchoalveolar
lung
bal
fluid
collect
everi
day
day
day
challeng
instil
aspir
ml
pb
describ
previous
day
challeng
one
two
calv
group
euthan
lung
excis
immedi
euthanasia
macroscop
lesion
record
score
extent
pneumon
consolid
seven
piec
tissu
right
cranial
cranial
caudal
portion
middl
caudal
lobe
excis
heparinis
blood
sampl
tenfold
dilut
rpmi
medium
gibco
belgium
supplement
mm
glutamin
uml
gentamycin
gml
fungizon
two
hundr
l
dilut
blood
sampl
incub
day
l
brsv
antigen
sonic
heatinactiv
cultur
supernat
primari
calf
kidney
cell
infect
viru
contain
tcid
ml
l
control
antigen
sonic
heatinactiv
cultur
supernat
primari
mockinfect
calf
kidney
cell
incub
ci
methyl
h
thymidin
l
rpmi
medium
ad
well
cell
collect
subsequ
h
incub
use
cell
harvest
radioact
incorpor
dna
measur
liquid
scintil
count
betapl
pharmacia
sweden
result
express
stimul
index
si
correspond
number
cpm
obtain
brsv
antigen
divid
number
cpm
obtain
control
prepar
si
cutoff
determin
mean
standard
deviat
si
valu
anim
vaccin
gammainterferon
product
measur
vitro
stimul
ml
heparinis
blood
l
brsv
control
antigen
amount
plasma
quantifi
elisa
bovin
easia
kit
biosourc
europ
result
express
stimul
index
si
correspond
od
obtain
brsv
antigen
divid
od
obtain
control
prepar
cutoff
si
valu
calcul
standard
deviat
mean
si
valu
calv
vaccin
serum
sampl
collect
calv
vaccin
day
challeng
day
challeng
subject
indirect
immunofluoresc
test
describ
previous
briefli
sera
serial
threefold
dilut
start
dilut
incub
slide
cover
brsv
infect
noninfect
primari
kidney
cell
wash
step
cell
incub
fitcconjug
rabbit
antibovin
igg
observ
fluoresc
microscop
slide
examin
without
inform
group
assign
local
humor
prime
investig
test
presenc
nspecif
igg
iga
bal
challeng
igg
antibodi
determin
indirect
elisa
use
purifi
n
protein
coat
antigen
incub
twofold
dilut
lba
start
test
reveal
use
hrpconjug
rabbit
antibovin
serum
tmb
substrat
nspecif
iga
antibodi
determin
essenti
describ
briefli
plate
coat
mab
bovin
iga
cedidiagnost
netherland
incub
twofold
dilut
lba
start
reaction
purifi
n
protein
reveal
use
biotinconjug
bovin
serum
brsv
hrpconjug
streptavidin
tmb
viral
load
bal
fluid
lung
investig
quantit
realtim
rtpcr
briefli
anim
piec
approxim
cm
lung
lobe
mix
togeth
ml
pb
use
ultraturrax
homogen
two
hundr
l
bal
fluid
l
homogen
extract
subject
rna
extract
cdna
synthesi
describ
previous
realtim
rtpcr
specif
brsv
bovin
betaactin
actb
perform
along
correspond
standard
curv
allow
quantif
result
express
number
brsv
rna
copi
per
actb
copi
bal
fluid
per
actb
copi
lung
necropsi
sampl
lesion
taken
pulmonari
lobe
sampl
store
neutral
buffer
formalin
embed
paraffin
section
stain
hematoxylin
eosin
histolog
examin
slide
examin
without
inform
group
assign
data
collect
group
compar
oneway
analysi
varianc
tukey
test
famili
error
rate
logarithm
transform
appli
lymphocyt
prolifer
si
si
ifi
titer
order
fulfil
condit
varianc
homogen
check
bartlett
test
normal
check
ryan
joiner
test
brsvspecif
lymphoprolif
respons
detect
calv
vaccin
twice
pnsyn
plasmid
fig
inject
n
protein
abl
induc
detect
lymphoprolif
respons
nonprim
anim
protein
boost
respons
calv
previous
vaccin
pnsyn
boost
calv
pnsynnpur
group
stimul
index
cutoff
consider
enhanc
brsvspecif
prolif
respons
time
calv
pnsyn
group
still
si
valu
cutoff
day
mean
si
valu
pnsynnpur
group
significantli
differ
mean
si
valu
group
p
remain
higher
mockvaccin
npur
group
challeng
p
brsv
challeng
induc
detect
respons
mockvaccin
group
contrast
lymphoprolif
respons
calv
vaccin
pnsyn
enhanc
mean
si
valu
group
significantli
differ
control
group
group
vaccin
n
protein
alon
p
twelv
day
challeng
calv
npur
group
also
show
low
level
prolif
respons
plasmid
vaccin
si
anim
remain
cutoff
fig
howev
protein
boost
anim
subject
pnsyn
plasmid
n
protein
vaccin
display
signific
product
compar
group
day
p
anim
vaccin
pnsyn
alon
also
prime
product
shown
signific
si
valu
week
challeng
day
day
si
group
vaccin
pnsyn
significantli
differ
group
p
mockvaccin
group
remain
neg
till
end
brsvspecif
antibodi
respons
measur
indirect
immunofluoresc
fig
pnsyn
prime
elicit
low
level
antibodi
increas
either
protein
boost
anim
pnsynnpur
group
challeng
anim
pnsyn
group
inject
n
protein
alon
also
induc
specif
seroconvers
time
challeng
mean
antibodi
titer
vaccin
group
significantli
differ
p
howev
antibodi
titer
vaccin
group
significantli
higher
mockvaccin
group
p
seroconvers
mockvaccin
anim
observ
day
challeng
consist
prime
effect
challeng
prime
local
respons
differ
vaccin
group
investig
measur
nspecif
igg
iga
bal
challeng
none
anim
exhibit
nspecif
igg
respons
day
challeng
anim
mockandpnsynvaccin
group
remain
neg
till
end
experi
igg
antibodi
detect
npur
group
day
challeng
maximum
mean
titer
pnsynnpur
group
posit
anim
record
day
challeng
maximum
mean
titer
day
challeng
data
shown
contrast
nspecif
iga
respons
detect
bal
whatev
vaccin
group
data
shown
challeng
fever
increas
respiratori
rate
record
three
anim
mockvaccin
group
experienc
mild
cough
last
least
day
challeng
consid
signific
data
shown
replic
challeng
brsv
follow
bal
fluid
collect
everi
day
quantit
realtim
rtpcr
fig
expect
calv
neg
day
challeng
viral
rna
detect
mockvaccin
calv
day
challeng
till
end
experi
howev
day
infect
almost
resolv
viral
load
bal
fluid
copi
viral
rna
similar
kinet
observ
calv
vaccin
n
protein
except
viru
clear
day
anim
prime
pnsyn
show
lower
brsv
rna
copi
number
bal
fluid
group
inde
anim
time
point
viral
load
rna
actb
copi
also
anim
posit
maximum
success
time
point
calv
clear
viru
day
postchalleng
howev
great
individu
variabl
low
number
anim
group
prevent
differ
group
vaccin
pnsyn
group
statist
signific
except
day
challeng
p
one
anim
group
kill
day
challeng
remain
anim
group
kill
day
lung
examin
presenc
pneumon
consolid
record
lobe
number
affect
lobe
group
summar
tabl
mockvaccin
group
calv
show
lesion
caudal
part
cranial
lobe
middl
accessori
lobe
cranial
part
cranial
lobe
affect
calv
caudal
one
calv
contrast
group
vaccin
pnsyn
n
protein
one
calf
show
one
spot
consolid
cranial
lobe
cranial
part
anoth
caudal
lobe
group
significantli
differ
mockvaccin
group
p
group
gave
intermedi
result
affect
anim
show
lesion
cranial
part
cranial
lobe
howev
differ
control
group
statist
support
lesion
also
less
sever
extent
group
control
group
except
one
anim
vaccin
n
protein
lobe
anim
affect
extent
lesion
compar
observ
mockvaccin
group
histolog
examin
lung
reveal
typic
brsv
lesion
histopatholog
lesion
bronchi
bronchiol
includ
lymphoid
peribronchi
cuf
fig
b
lymphoid
infiltr
hyperplasia
metaplasia
epithelium
desquam
presenc
syncyti
cell
lumen
fig
infiltr
mononuclear
inflammatori
cell
consolid
emphysema
record
alveoli
fig
f
howev
irrespect
slaughter
time
postchalleng
day
day
lesion
less
sever
limit
group
vaccin
pnsyn
npur
fig
c
e
group
fig
f
viral
replic
lung
analyz
quantit
realtim
rtpcr
tabl
brsv
rna
detect
lung
calv
vaccin
pnsyn
alon
calv
prime
pnsyn
boost
n
protein
two
calv
vaccin
n
protein
alon
also
protect
contrast
brsv
rna
detect
lung
mockvaccin
anim
numer
advantag
describ
use
dna
vaccin
theoret
combin
efficaci
live
vaccin
safeti
afford
inactiv
vaccin
circumv
inhibitori
effect
matern
antibodi
prime
compon
immun
respons
particular
interest
overcom
bia
vaccin
neonat
brsv
sever
studi
describ
vaccin
mice
plasmid
express
f
g
glycoprotein
antigen
also
test
vaccin
candid
calv
plasmid
express
g
glycoprotein
afford
partial
reduct
viral
shed
challeng
recent
anim
pulmonari
lobe
examin
presenc
pneumon
consolid
ratio
anim
present
lesion
indic
lobe
total
number
affect
lobe
group
also
present
dna
vaccin
encod
brsv
fusion
protein
induc
signific
protect
viru
challeng
reduc
nasopharyng
excret
viru
extent
gross
pneumon
lesion
howev
complet
protect
brsv
confer
final
dna
immun
infant
rhesu
monkey
young
calv
brsv
f
nucleocapsid
n
protein
stimul
humor
cellmedi
immun
viru
reduc
viral
replic
clinic
sign
pulmonari
lesion
challeng
report
describ
use
n
protein
rather
scarc
howev
n
shown
major
target
immun
respons
rsv
vaccin
mice
recombin
vaccinia
viru
encod
h
rsv
n
protein
induc
partial
resist
similarli
immun
young
calv
recombin
vaccinia
viru
express
brsv
n
protein
induc
nonneutr
antibodi
prime
brsvspecif
prolif
respons
product
result
reduct
viral
replic
upper
lower
respiratori
tract
overal
data
suggest
protect
afford
n
protein
might
larg
mediat
cellular
immun
efficaci
dna
immun
n
protein
alon
never
studi
present
studi
purpos
work
thu
first
stimul
cellular
immun
respons
use
dna
vaccin
enhanc
respons
proteic
boost
therefor
use
nucleocapsid
n
protein
brsv
primeboost
vaccin
strategi
compar
use
dna
protein
vaccin
alon
present
studi
show
cellular
humor
arm
immun
respons
stimul
vaccin
combin
inject
either
pnsyn
npur
induc
brsvspecif
humor
respons
neutral
activ
antibodi
investig
antibodi
n
protein
shown
nonneutr
other
time
challeng
howev
signific
differ
vaccin
group
furthermor
vaccin
prime
local
nspecif
iga
respons
accord
result
tabl
viral
load
lung
examin
conduct
quantit
realtim
rtpcr
total
rna
extract
homogen
piec
differ
pulmonari
lobe
publish
other
inde
vaccin
recombin
vaccinia
viru
express
n
protein
induc
local
iga
respons
lymphoprolif
respons
induc
calv
receiv
pnsyn
plasmid
respons
increas
calv
boost
n
protein
result
significantli
higher
stimul
index
compar
group
contrast
primeboost
combin
induc
product
challeng
clinic
virolog
protect
evalu
clinic
sign
record
even
mockvaccin
anim
contrast
previou
experi
stock
brsv
use
reason
unclear
could
link
age
genet
background
anim
howev
viru
replic
respiratori
tract
mockvaccin
anim
highest
viral
load
observ
bal
day
postinfect
autopsi
viral
load
lung
high
previous
describ
gross
pneumon
well
histopatholog
lesion
observ
inject
n
protein
calv
protect
brsv
replic
lung
howev
high
viral
load
detect
bal
fluid
protect
pneumon
lesion
partial
dna
vaccin
alon
abl
protect
viral
replic
lung
strongli
reduc
viral
replic
bal
calv
total
protect
develop
gross
pneumon
lesion
presenc
lung
consolid
autopsi
indic
spread
viru
lung
inde
patholog
chang
shown
appear
replic
brsv
spread
alveoli
may
continu
clearanc
viru
contrast
protect
viral
replic
lung
gross
histolog
pneumon
lesion
afford
combin
dna
protein
vaccin
suggest
infecti
viru
clear
infect
alveoli
role
cellular
immun
protect
rsv
pathogenesi
induc
viru
controversi
bovin
shown
induc
respons
character
product
one
hand
cell
elimin
viru
also
caus
immunopatholog
mice
identifi
key
molecul
involv
viru
control
immunopatholog
induc
cell
mice
bias
cell
respons
could
either
coexist
regul
hand
impair
viral
clearanc
enhanc
diseas
observ
vaccin
fi
vaccin
correl
decreas
product
formul
fibrsv
cpg
odn
result
increas
secret
reduct
gross
lung
patholog
viral
replic
calv
mice
furthermor
modifi
live
vaccin
induc
cellular
immun
particular
secret
peripher
blood
leukocyt
appear
consist
correl
protect
prechalleng
serum
antibodi
data
consist
result
inde
anim
protect
viral
replic
lung
develop
macroscop
lung
lesion
result
brsv
challeng
vaccin
success
pnsyn
n
protein
exhibit
signific
product
time
challeng
inject
purifi
n
protein
mix
quil
induc
measur
lymphoprolif
respons
anticip
author
show
insect
cell
infect
recombin
baculoviru
express
f
protein
mix
quil
stimul
cellularmedi
immun
respons
lamb
howev
baculoviru
shown
stimul
immun
respons
could
contribut
overal
effect
immunogen
experi
n
protein
nevertheless
abl
prime
lymphoprolif
respons
detect
brsv
challeng
might
attribut
trigger
adjuv
vaccin
n
protein
calv
protect
viral
replic
lung
viru
detect
lung
remain
calf
calf
interestingli
calf
also
higher
viral
load
bal
fluid
extend
lesion
lung
compar
calv
group
calv
show
ident
serolog
respons
howev
lymphoprolif
respons
individu
examin
blood
collect
day
challeng
si
calf
calv
data
shown
hypothes
develop
pulmonari
lesion
viral
replic
lung
correl
absenc
cellmedi
immun
primeboost
strategi
use
superior
dna
protein
vaccin
alon
term
protect
larg
anim
accord
result
publish
other
inde
strategi
recent
shown
induc
stronger
humor
immun
respons
better
protect
bvdv
cattl
compar
immun
dna
protein
alon
boost
dna
vaccin
mice
recombin
vector
elicit
strong
immun
respons
furthermor
shown
longev
tcell
stimul
higher
dna
primemlv
boost
mlv
vaccin
alon
cattl
boost
respons
inactiv
viru
recombin
protein
controversi
inactiv
viral
boost
shown
enhanc
antibodi
respons
respons
sever
acut
respiratori
syndrom
coronaviru
mice
author
describ
enhanc
ctl
thelper
cell
hiv
protein
boost
nonhuman
primat
also
although
cytotox
cell
respons
investig
increas
lymphoprolif
respons
product
observ
suggest
enhanc
cellular
respons
protein
boost
conclus
result
present
show
protect
brsv
replic
lung
lung
patholog
nucleocapsidbas
dna
primeprotein
boost
protocol
vaccin
strategi
elicit
humor
cellular
immun
respons
observ
protect
correl
lymphoprolif
respons
product
result
also
confirm
efficaci
primeboost
strategi
larg
anim
model
strategi
promis
protect
rsv
cattl
could
also
open
perspect
vaccin
young
infant
well
work
perform
confirm
present
result
neonat
calv
harbor
matern
antibodi
final
develop
would
combin
nucleocapsid
fusion
protein
dna
primeprotein
boost
strategi
order
stimul
protect
cellular
immun
neutral
antibodi
